Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Mar;35(1):75-83.
doi: 10.1080/02813432.2017.1288812. Epub 2017 Feb 28.

Symptom Load and General Function Among Patients With Erythema Migrans: A Prospective Study With a 1-year Follow-Up After Antibiotic Treatment in Norwegian General Practice

Affiliations
Free PMC article
Randomized Controlled Trial

Symptom Load and General Function Among Patients With Erythema Migrans: A Prospective Study With a 1-year Follow-Up After Antibiotic Treatment in Norwegian General Practice

Knut Eirik Eliassen et al. Scand J Prim Health Care. .
Free PMC article

Abstract

Objective: Promptly treated erythema migrans (EM) has good prognosis. However, some patients report persistent symptoms. Do patients with EM have more symptoms than the general population? We describe individual symptoms and general function in EM-patients at time of diagnosis and one year after treatment.

Design: Prospective study with 1-year follow up after treatment. Questionnaires included a modified version of the Subjective Health Complaints Inventory, comprising three additional Lyme borreliosis (LB) related symptoms. General function was assessed using a five-point scale modified from the COOP/WONCA charts.

Setting: Norwegian general practice.

Subjects: A total of 188 patients were included in a randomized controlled trial comparing three antibiotic regimens for EM, of whom 139 had complete data for this study.

Main outcome measures: Individual symptoms, symptom load and general function.

Results: Mild symptoms were common, reported by 84.9% at baseline and by 85.6% at follow-up. At baseline, patients reported a mean of 5.4 symptoms, compared with 6.2 after one year. Severely bothersome symptoms and severely impaired general function were rare. Tiredness was the most reported symptom both at baseline and at follow-up. Palsy (other than facial) was the least reported symptom, but the only one with a significant increase. However, this was not associated to the EM.

Conclusion: The symptom load was comparable to that reported in the general population. We found an increase in symptom load at follow-up that did not significantly affect general function.

Implication: Monitoring patients' symptom loads prior to treatment reduce the probability of attributing follow-up symptoms to LB. Key points Erythema migrans has a good prognosis.Patients treated for erythema migrans have a slight increase in symptom load one year after treatment. This increase does not affect general function. The levels of subjective health complaints in patients treated for erythema migrans are comparable to the background population.

Keywords: Lyme borreliosis; Norway; erythema migrans; general practice; self-reported symptoms; subjective health complaints.

Figures

Figure 1.
Figure 1.
(A) Severity level I. The numbers of symptoms reported to be at least a little bothersome among patients clinically diagnosed with EM at baseline and at the 1-year follow-up (n = 139). (B) Severity level II. The numbers of symptoms reported to be at least a moderately bothersome among patients clinically diagnosed with EM at baseline and at the 1-year follow-up (n = 139). (C) Severity level III. The numbers of symptoms reported to be severely bothersome among patients clinically diagnosed with EM at baseline and at the 1-year follow-up (n = 139).

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Stanek G, Wormser GP, Gray J, et al. Lyme borreliosis. Lancet. 2012;379:461–473. - PubMed
    1. Nygard K, Brantsaeter AB, Mehl R. Disseminated and chronic Lyme borreliosis in Norway, 1995–2004. Euro Surveill. 2005;10:235–238. - PubMed
    1. Lindgren E, Jaenson TGT. Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. Copenhagen, Denmark: WHO Regional Office for Europe; 2006.
    1. Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med. 2002;136:421–428. - PubMed
    1. Bennet L, Fraenkel CJ, Garpmo U, et al. Clinical appearance of erythema migrans caused by Borrelia afzelii and Borrelia garinii – effect of the patient’s sex. Wien Klin Wochenschr. 2006;118:531–537. - PubMed

Publication types

MeSH terms

Substances

Grant support

Funding for the study was granted by the Institute of Health and Society within the University of Oslo and the Norwegian Research Fund for General Practice (http://legeforeningen.no/Allmennmedisinsk-forskningsfond/). Additional funding was received from the Antibiotic Centre for Primary Care, the NORM surveillance program for antibiotic resistance in human pathogens, the National Centre of Rural Medicine, and the Eckbo Trust. None of those providing economic support were involved in the study design, data collection, analysis and interpretation of data, writing of the report, or in the decision to submit the article for publication.
Feedback